USSTOCK.TODAY
Weekend. Closed Log in Sign up

Centessa Pharmaceuticals plc ADR(CNTA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

Halted
Trading Halted Since 2026-07-17: Trading has been halted. It may resume, and prices shown reflect the last trading day.
CNTA
CNTA
Halted
Centessa Pharmaceuticals plc ADR
$40.50
+0.00 +0.00%

Full metrics table

Index ⓘ -P/E ⓘ -EPS (ttm) ⓘ -1.77Insider Own ⓘ 29.35%Shs Outstand ⓘ 154.7MPerf Week ⓘ -
Market Cap ⓘ 6.27BForward P/E ⓘ -EPS next Y ⓘ -9.13%Insider Trans ⓘ -0.81%Shs Float ⓘ 109.3MPerf Month ⓘ 1.61%
Enterprise Value ⓘ 6.11BPEG ⓘ -EPS next Q ⓘ -0.39Inst Own ⓘ 70.86%Short Float ⓘ 1.47%Perf Quarter ⓘ 1.96%
Income ⓘ -0.25BP/S ⓘ -EPS this Y ⓘ -14.38%Inst Trans ⓘ -Short Ratio ⓘ 0.55Perf Half Y ⓘ 63.37%
Sales ⓘ 0.00BP/B ⓘ 12.86EPS next 5Y ⓘ 62.02%ROA ⓘ -42.87%Short Interest ⓘ 1.61MPerf YTD ⓘ 61.94%
Book/sh ⓘ 3.15P/C ⓘ 22.66EPS past 3/5Y ⓘ 14.25% -130.75%ROE ⓘ -57.39%52W High ⓘ -0.15% ($40.56)Perf Year ⓘ 211.54%
Cash/sh ⓘ 1.79P/FCF ⓘ -Sales past 3/5Y ⓘ -ROIC ⓘ -41.43%52W Low ⓘ 217.9% ($12.74)Perf 3Y ⓘ 513.64%
Dividend Est. ⓘ -EV/EBITDA ⓘ -EPS Y/Y TTM ⓘ 1.57%Gross Margin ⓘ -Volatility(W/M) ⓘ 0.7% 0.45%Perf 5Y ⓘ 70.24%
Dividend TTM ⓘ -EV/Sales ⓘ -Sales Y/Y TTM ⓘ -100%Oper. Margin ⓘ -ATR (14) ⓘ 0.23Perf 10Y ⓘ -
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 9.53EPS Q/Q ⓘ -161.26%Profit Margin ⓘ -RSI (14) ⓘ 78.17Recom ⓘ 3
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 9.53Sales Q/Q ⓘ -100%SMA20 ⓘ 1.65% ($39.84)Beta ⓘ 1.13Target Price ⓘ $42.67
Payout ⓘ -Debt/Eq ⓘ 0.24Earnings ⓘ 2026/05/18SMA50 ⓘ 2.05% ($39.69)Rel Volume ⓘ 0Prev Close ⓘ $40.5
Employees ⓘ 118LT Debt/Eq ⓘ 0.24EPS/Sales Surpr. ⓘ -28.4% -SMA200 ⓘ 38.66% ($29.21)Avg Volume(3M) ⓘ 2.92MPrice ⓘ $40.5
IPO ⓘ 2021/5/28Option/Short ⓘ Yes/NoTrades ⓘ 0Volume ⓘ -Change ⓘ -
Company
CNTA CNTACentessa Pharmaceuticals plc ADR | NASD | Biotechnology Deep dive

A U.S.-listed American Depositary Receipt (ADR) of a clinical-stage biotech company developing therapeutics for sleep and wakefulness disorders. Its core program focuses on oral orexin receptor agonists targeting sleep disorders such as narcolepsy. As a biotech healthcare stock, its share price is driven by clinical trial results for its key late-stage candidate and its funding situation.

Quote

Over the past 1 year, on the higher side

0% below its 1-year high.

Now $40.50
52w low$12.7452w high$40.56
52W Range100%
Volume ⓘ 0

Traded less than usual. That is 0% of its average volume.

A
Overall · mostly strong
We judged 5 of the 8 questions below. 3 rate excellent and 1 need caution.
No data for valuation, earnings, dividends, or not applicable.
ETFs holding this stock 5 ETFs

Multiple ETFs hold this stock, but only a sliver

Buying this ETF gives you exposure to this stock as well.

Peer comparison Biotechnology

It ranks #42 of 599 in the industry

Based on market cap of $6B.

FAQ

FAQ

CNTA belongs to the Healthcare sector and operates in the Biotechnology industry.

The market cap of CNTA is approximately $6.3B, ranking 1,244 within its sector.

CNTA has recorded a 52-week high of $40.56 and a low of $12.74.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels